# Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/trastuzumab-deruxtecan-t-dxd-ds-8201-in-patients-pts-with-her2-expressing/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Akihiro Ohba,Chigusa Morizane,Yasuyuki Kawamoto,Yoshito Komatsu,Makoto Ueno,Satoshi Kobayashi,Masafumi Ikeda,Mitsuhito Sasaki,Junji Furuse,Naohiro Okano,Nobuyoshi Hiraoka,Hiroshi Yoshida,Aya Kuchiba,Ryo Sadachi,Kenichi Nakamura,Naoko Matsui,Yoshiaki Nakamura,Wataru Okamoto,Takayuki Yoshino,Takuji Okusaka |
| Citations | 108 |
| DOI | 10.1200/jco.2022.40.16_suppl.4006 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4286294450 |
| Type | conference-abstract |
| Year | 2022 |

## Paper authors

- [Satoshi Kobayashi](https://scholariq.org/researchers/satoshi-kobayashi/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

## Paper topics

- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.